Developing 21st Century Medicines
SCIENCE
Tomorrow's Medicines
Start Here
Targeted Medicines Built on Proprietary Peptide Platforms
SMDG is developing targeted, potentially disease-modifying medicines using our proprietary NanoLigand™ platforms, invented by Professor Moein Moghimi. Built from engineered peptides, these platforms combine biological target recognition, self-assembly and receptor-mediated transport to create functional therapeutic nanosystems.
Our platforms support the development of medicines incorporating a range of therapeutic agents, including nucleic acids, for neurological, rare pediatric, inflammatory and oncological diseases where biological barriers limit conventional treatment.
Proprietary NanoLigand
Therapeutic Platforms
TM
NanoLigand Carriers™ (NLCs)
NanoLigand Carriers™ are proprietary, self-assembling peptidomimetic nanosystems designed for receptor-mediated targeting across the blood–brain barrier and other biological barriers. NLCs can incorporate a range of therapeutic agents, including nucleic acids, to support the development of targeted, potentially disease-modifying medicines. Their modular design is guided by SMDG’s Safe-by-Design and Simple-by-Design principles.
NanoLigand Blocks™ (NLBs)
NanoLigand Blocks™ are proprietary, self-assembling peptidomimetic nanosystems designed to engage defined biological targets and support targeted therapeutic development. Their adaptable design offers potential applications across neurological, inflammatory, oncological and other diseases with significant unmet medical need.
Platform Capabilities
NanoLigand™ platforms combine biological target recognition, self-assembly and receptor-mediated transport to support the development of targeted therapeutics across multiple disease areas.
Simple and Safe Design
Guided by Safe-by-Design and Simple-by-Design principles, with careful consideration of biological interactions, immune safety and manufacturability.
Enabling Active Targeting
Engineered peptides recognize defined biological targets, supporting receptor-mediated transport and targeted therapeutic development.
Adaptable Therapeutic Design
Designed to incorporate a range of therapeutic agents, including nucleic acids, and to support different therapeutic strategies and disease applications.
Broad Therapeutic Applications
Applicable across neurological, rare pediatric, inflammatory and oncological diseases with significant unmet medical need.
Precision Genetic Medicines
Combining next-generation nucleic acid therapeutics with proprietary peptide-based platforms
Designing the Next Generation of Genetic Medicines
At SMDG, we combine disease biology, nucleic acid therapeutic design and proprietary peptide-based platforms to develop targeted genetic medicines. Our NanoLigand™ technologies are engineered to support receptor-mediated transport across biological barriers and enable therapeutic agents to reach their intended tissues and cells.
We are applying this integrated approach to develop first-in-class, potentially disease-modifying therapies for neurological, rare pediatric, inflammatory and oncological diseases with significant unmet medical need.
